- Denali Therapeutics (NasdaqGS:DNLI) has regained full global rights to DNL593 for frontotemporal dementia granulin, after Takeda ended its collaboration.
- DNL593 uses Denali's TransportVehicle technology to deliver progranulin to the brain for patients with FTD-GRN.
- Denali plans to continue clinical development of DNL593 independently, with Phase 1/2 study results expected by the end of 2026.
Denali Therapeutics focuses on treatments for neurodegenerative diseases, an area where current options are limited and patient need is high. The company’s TransportVehicle platform is central to its efforts to move large molecules into the brain, and DNL593 sits within this broader effort to address genetically defined forms of dementia. For readers following biotech, this update adds another data point on how drug developers structure and reshape partnerships as programs advance.
For investors watching NasdaqGS:DNLI, the return of full rights to DNL593 concentrates both the risks and potential rewards of this asset with Denali. Attention is likely to focus on clinical execution, regulatory interactions, and how the company allocates capital across its pipeline as it takes sole responsibility for this program.
Stay updated on the most important news stories for Denali Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Denali Therapeutics.
3 things going right for Denali Therapeutics that this headline doesn't cover.
Quick Assessment
- ✅ Price vs Analyst Target: At US$20.65, the share price sits about 43% below the US$36.14 analyst target.
- ✅ Simply Wall St Valuation: The stock is assessed as trading 38.9% below estimated fair value.
- ✅ Recent Momentum: The 30 day return is roughly 3.1%, showing modest positive short term performance.
There is only one way to know the right time to buy, sell or hold Denali Therapeutics. Head to Simply Wall St's company report for the latest analysis of Denali Therapeutics's Fair Value.
Key Considerations
- 📊 Regaining full rights to DNL593 concentrates upside and development risk on Denali, especially as the program targets a high need indication.
- 📊 Monitor cash usage, clinical milestones for the Phase 1/2 study, and any updates on timelines or trial design for DNL593.
- ⚠️ The company currently reports US$0 revenue and a recent net loss of US$512.54m, so funding and execution risk around the pipeline remain central.
Dig Deeper
For the full picture, including more risks and rewards, see the complete Denali Therapeutics analysis. You can also visit the community page for Denali Therapeutics to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com